Combination immunotherapy for high-risk resected and metastatic melanoma patients.

Riker, Adam I; Rossi, Gabriela R; Masih, Prerna; Alsfeld, L C; Denham, Fiona; Tennant, Lucinda; Ramsey, W Jay; Vahanian, Nicholas N; Link, Charles J

Riker, Adam I; Rossi, Gabriela R; Masih, Prerna; Alsfeld, L C; Denham, Fiona; Tennant, Lucinda; Ramsey, W Jay; Vahanian, Nicholas N; Link, Charles J.

Afiliação

Riker AI; Department of Surgery, Advocate Cancer Institute, Advocate Christ Medical Center, Oak Lawn, IL.
Rossi GR; NewLink Genetics, Ames, IA.
Masih P; NewLink Genetics, Ames, IA.
Alsfeld LC; Department of Internal Medicine, Medical University of South Carolina, Charleston, SC.
Denham F; Department of General Surgery, Carilion Clinic, Roanoke, VA.
Tennant L; NewLink Genetics, Ames, IA.
Ramsey WJ; NewLink Genetics, Ames, IA.
Vahanian NN; NewLink Genetics, Ames, IA.
Link CJ; NewLink Genetics, Ames, IA.

Ochsner J ; 14(2): 164-74, 2014.

Article em En | MEDLINE | ID: mdl-24940124

Palavras-chave

Alpha-galactosyl epitope; immunotherapy; melanoma; peginterferon alfa-2b; vitiligo

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Ochsner J Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google